ClinicalTrials.gg
RecruitingNCT07128199REZILIENT4Updated Oct 13, 2026

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

A Phase 3 interventional study of TAS6417 and Zipalertinib Matching-placebo in Lung Cancer, Adjuvant and Post-surgical, sponsored by Taiho Oncology, Inc.. Recruiting at 253 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,459 studies in Lung Neoplasms with a site in United States — 422 open to participants now, 644 under way, 53 of them phase 3. Lung Neoplasms · United States.

Planned enrollment
211th of 1,905
360 · median 48
Started
2025
with 103 others
Phase 3
158 of 2,459
24 open now
Primary completion
2029-10
later than 558 of 638 live
Registered
2,333rd of 2,459
by date

Among the 2,459 studies in Lung Neoplasms with a site in United States, this one is the 211th largest by planned enrollment of the 1,905 interventional ones that give a count, is one of 104 that started in 2025, is one of 158 in phase 3, reaches primary completion later than 558 of the 638 other live ones, and was the 2,333rd registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

422 of the 2,459 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:

417 more — sign in →

All 422 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,459 studies in Lung Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).

Read the detailed description

This study will evaluate zipalertinib, a novel EGFR tyrosine kinase inhibitor (TKI) versus placebo in participants with resected early stage NSCLC harboring uncommon EGFRmt.

Approximately 360 participants will be randomized to:

Arm A: Zipalertinib twice daily (BID) monotherapy OR

Arm B: Placebo BID monotherapy.

An independent data monitoring committee (IDMC) will be established to monitor interim safety data.

03

Conditions studied

  • Lung Cancer
  • Adjuvant
  • Post-surgical
  • EGFR
  • Exon 20
  • Early Stage Lung Cancer
  • Uncommon EGFR Mutations
  • NSCLC, Early Stage
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.
  2. Documented EGFRmt status as determined by local testing performed at a clinical laboratory improvement amendment (CLIA) certified (United States [US]) or accredited (outside of the US) local laboratory, defined as either one of the following EGFRmt:

    1. exon20 insertion mutations (ex20ins) or
    2. other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I) exons 18-21 of the EGFR tyrosine kinase domain
  3. Baseline imaging assessment of the brain (MRI [preferred modality] or CT scan) performed within 8 weeks prior to randomization must show no evidence of
  4. Complete surgical resection of the primary NSCLC is mandatory with negative surgical margins and systematic lymph node sampling or dissection.
  5. Complete recovery from surgery, including post-operative wound healing, and prior chemotherapy (if applicable) at the time of randomization. Randomization timing is defined as follows:

    1. For participants without prior adjuvant chemotherapy: 4 weeks and 12 weeks following surgery.
    2. For participants with prior adjuvant chemotherapy: 4 weeks and 8 weeks after the last dose of adjuvant chemotherapy.
  6. performance status (ECOG PS) of 0 or 1.
  7. Pathologic (post-operative) Stage IB, IIA, IIB, or IIIA according to the AJCC 9th tumor nodes (TNM) staging system for lung cancer. In addition, participants with stage IIIB are eligible when regional lymph node involvement is N2.
  8. available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers.

Exclusion criteria

Exclusion Criteria:

  1. Is currently receiving an drug in a clinical trial or participating in any other type of medical research.
  2. Treatment with any of the following within the time frame specified:

    1. Zipalertinib (TAS6417/CLN-081) or any other EGFR inhibitor at any time.
    2. Pre-operative or post-operative or planned radiation therapy for the current lung cancer.
    3. Any prior systemic anticancer therapy for NSCLC, including preoperative () chemotherapy, immunotherapy, or investigational therapy. (Exception: Participants who have received postoperative adjuvant platinum-based chemotherapy up to 4 cycles are permitted)
    4. Major surgery (including primary tumor surgery, excluding placement of vascular access) within 4 weeks prior to the first dose of study treatment.
    5. Treatment with an investigational drug within five half-lives of the compound or any of its related material, if known.
  3. Has received only wedge resections (complete anatomic segmentectomy is acceptable).
  4. Past medical history of interstitial lung disease (ILD)/pneumonitis, drug-induced ILD/pneumonitis or any evidence of clinically active ILD/pneumonitis.
  5. Unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal (GI) absorption of zipalertinib (such as inflammatory bowel disease, malabsorption syndrome, or prior significant bowel resection).
  6. Has a history of any other cancer except for any of the following:

    1. Non-melanoma skin cancer treated with curative intent
    2. Carcinoma in situ treated with curative intent
    3. Other curatively treated cancer, with no evidence of disease for >3 years following the end of treatment and, in the opinion of the treating physician, has no substantial risk of recurrence.
    4. Concurrent of which natural history does not have the potential to interfere with the safety or efficacy assessment (eg, Gleason 6 prostate cancer)
  7. Known history of , , or (HIV) that is unstable or not controlled with treatment.
  8. Active bleeding disorders.
  9. Known to the ingredients in zipalertinib/placebo or any drugs similar in structure or class.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Zipalertinib

    Participants will receive zipalertinib orally until the participant meets any of the treatment discontinuation criteria.

    Drug: TAS6417

  • Placebo comparator
    Placebo

    Participants will receive zipalertinib matching-placebo, until the participant meets any of the treatment discontinuation criteria.

    Drug: Zipalertinib Matching-placebo

Interventions

  • Oral tablets.

    Also known as: Zipalertinib, CLN-081

  • DrugZipalertinib Matching-placebo

    Oral tablets.

06

What researchers measure

Primary outcomes

  1. Disease-free Survival (DFS) as Assessed by the Investigator

    Time frame: Up to 5 years

Secondary outcomes

  1. Disease-free Survival Rate

    Time frame: Up to 5 years

  2. Overall Survival (OS)

    Time frame: Up to 5 years

  3. Overall Survival Rate

    Time frame: Up to 5 years

  4. DFS of Central Nervous System (cDFS)

    Time frame: Up to 5 years

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs) Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)

    Time frame: Up to 5 years

  6. Number of Participants with Clinically Significant Changes in Clinical Laboratory Parameters

    Time frame: Up to 5 years

  7. Number of Participants with Clinically Significant Changes in Vital Signs

    Time frame: Up to 5 years

  8. Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Parameters

    Time frame: Up to 5 years

  9. Number of Participants With Change in Left Ventricular Ejection Fraction (LVEF) Evaluated Using Electrocardiography (ECHO) and Multigated Acquisition (MUGA) Scan

    Time frame: Up to 5 years

  10. Change in EuroQuality of Life-5 Dimensional 3-Level (EQ-5D-3L)

    EQ-5D-3L is a standardized measure of the participant's health-related quality of life (QoL). EQ-5D is a 5-item questionnaire that assesses 5 domains.

    Time frame: Baseline, up to 5 years

  11. Change From Baseline in European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30) Scores

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale.

    Time frame: Up to 5 years

07

Study locations

108 of 253 sites recruiting
  • Alaska Oncology and Hematology
    Anchorage, Alaska 99508, United States
    Recruiting
  • City of Hope Comprehensive Cancer Center - Duarte
    Duarte, California 91010, United States
    Not yet recruiting
  • City of Hope Comprehensive Cancer Center Orange County Lennar Foundation Cancer Center
    Irvine, California 92618, United States
    Not yet recruiting
  • Scripps Clinic Torrey Pines
    La Jolla, California 92037, United States
    Not yet recruiting
  • Kaiser Permanente - Vallejo Medical Center
    Vallejo, California 94589, United States
    Not yet recruiting
  • Georgetown University School of Medicine
    Washington D.C., District of Columbia 20007, United States
    Recruiting
  • D&H Cancer Research Center - Margate
    Margate, Florida 33063, United States
    Recruiting
  • Alpha Oncology Research
    Orange City, Florida 32763, United States
    Recruiting
  • City of Hope - Atlanta
    Newnan, Georgia 30265, United States
    Not yet recruiting
  • University of Illinois Medical Center
    Chicago, Illinois 60612, United States
    Recruiting
  • Profound Research LLC at Michigan Hematology and Oncology Consultants
    Dearborn, Michigan 48126, United States
    Recruiting
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
    Not yet recruiting
  • Memorial Sloan Kettering Cancer Center - Basking Ridge
    Basking Ridge, New Jersey 07920, United States
    Not yet recruiting
  • Memorial Sloan Kettering Cancer Center - Monmouth
    Middletown, New Jersey 07748, United States
    Not yet recruiting
  • Memorial Sloan Kettering Cancer Center - Bergen
    Montvale, New Jersey 07645, United States
    Not yet recruiting
  • Memorial Sloan Kettering Cancer Center - Commack
    Commack, New York 11725, United States
    Not yet recruiting
  • Memorial Sloan Kettering Cancer Center - Westchester
    East White Plains, New York 10604, United States
    Not yet recruiting
  • Long Island Jewish Medical Center
    Lake Success, New York 11042, United States
    Not yet recruiting
  • Perlmutter Cancer Center - 34th Street
    New York, New York 10016, United States
    Not yet recruiting
  • Memorial Sloan Kettering Cancer Center - New York
    New York, New York 10065, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Center - Nassau
    Uniondale, New York 11553, United States
    Not yet recruiting
  • Atrium Health Wake Forest Baptist - Comprehensive Cancer Center
    Charlotte, North Carolina 28204, United States
    Not yet recruiting
  • Durham Veterans Affairs Health Care System
    Durham, North Carolina 27705, United States
    Not yet recruiting
  • Gabrail Cancer and Research Center
    Canton, Ohio 44718, United States
    Recruiting
  • Gibbs Cancer Center and Research Institute Spartanburg
    Spartanburg, South Carolina 29303, United States
    Not yet recruiting
  • Virginia Cancer Specialists - Arlington Office
    Arlington, Virginia 22201, United States
    Not yet recruiting
  • Virginia Cancer Specialists - Fairfax Office
    Fairfax, Virginia 22031, United States
    Recruiting
  • Virginia Cancer Specialists - Bristow Office
    Manassas, Virginia 20110, United States
    Not yet recruiting
  • Virginia Cancer Specialists - Reston
    Reston, Virginia 20190, United States
    Not yet recruiting
  • Virginia Cancer Specialists - Woodbridge Office
    Woodbridge, Virginia 22191, United States
    Not yet recruiting
  • Instituto Argentino de Diagnóstico y Tratamiento
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1122, Argentina
    Not yet recruiting
  • Centro de Investigación Pergamino SA
    Pergamino, Buenos Aires B2700KMP, Argentina
    Not yet recruiting
  • Hospital Universitario Austral
    Pilar, Buenos Aires B1629AHJ, Argentina
    Not yet recruiting
  • CEMAIC - Centro de Especialidades Médicas Ambulatorias e Investigación Clínica
    Córdoba, Córdoba Province X5008HHW, Argentina
    Not yet recruiting
  • Bankstown-Lidcombe Hospital
    Bankstown, New South Wales 2200, Australia
    Not yet recruiting
  • GenesisCare - North Shore
    St Leonards, New South Wales 2065, Australia
    Recruiting
  • Saint John of God - Subiaco Hospital
    Subiaco, Western Australia 6008, Australia
    Recruiting
  • Universitair Ziekenhuis Antwerpen
    Edegem, Antwerpen 2650, Belgium
    Not yet recruiting
  • Algemeen Ziekenhuis Sint-Maarten
    Mechelen, Antwerpen 2800, Belgium
    Not yet recruiting
  • Universitair Ziekenhuis (UZ) Leuven - Campus Gasthuisberg
    Leuven, Flemish Brabant 3000, Belgium
    Not yet recruiting
  • NOHC - Núcleo de Oncologia e Hematologia do Ceará - José Lourenço
    Fortaleza, Ceará 60115-281, Brazil
    Not yet recruiting
  • Centro Regional Integrado de Oncologia
    Fortaleza, Ceará 60335-480, Brazil
    Not yet recruiting
  • Centro de Pesquisas Clínicas Em Oncologia - CPCO
    Cachoeiro de Itapemirim, Espírito Santo 29308-065, Brazil
    Not yet recruiting
  • Hospital Santa Rita
    Vitória, Espírito Santo 29043-260, Brazil
    Not yet recruiting
  • Núcleo de Oncologia da Bahia Ondina - NOB
    Salvador, Estado de Bahia 40170-110, Brazil
    Not yet recruiting
  • Oncoclinicas Oncovida - Brasilia
    Brasília, Federal District 70390-150, Brazil
    Not yet recruiting
  • Cetus Oncologia - Unidade Belo Horizonte
    Belo Horizonte, Minas Gerais 30110-022, Brazil
    Not yet recruiting
  • Cenantron Centro Avançado de Tratamento Oncológico
    Belo Horizonte, Minas Gerais 30130-090, Brazil
    Not yet recruiting
  • Centro Integrado de Oncologia de Curitiba (CIONC)
    Curitiba, Paraná 80810-050, Brazil
    Not yet recruiting
  • Instituto de Medicina Integral Professor Fernando Figueira
    Recife, Pernambuco 50070-902, Brazil
    Not yet recruiting
  • Centro de Pesquisa Vencer e Oncoclínica - Teresina
    Teresina, Piauí 64.049-200, Brazil
    Not yet recruiting
  • Instituto D'Or de Pesquisa e Ensino - Rio de Janeiro
    Botafogo, Rio de Janeiro 22281-100, Brazil
    Not yet recruiting
  • Liga Contra o Câncer - Centro Avançado de Oncologia
    Natal, Rio Grande do Norte 59062-000, Brazil
    Not yet recruiting
  • Clínica Viver
    Centro Santa Maria, Rio Grande do Sul 97015-450, Brazil
    Not yet recruiting
  • Hospital Bruno Born
    Lajeado, Rio Grande do Sul 95900-022, Brazil
    Not yet recruiting
  • Hospital São Vicente de Paulo
    Passo Fundo, Rio Grande do Sul 99010-090, Brazil
    Not yet recruiting
  • Irmandade da Santa Casa de Misericórdia Hospital - Porto Alegre
    Porto Alegre, Rio Grande do Sul 90050-170, Brazil
    Not yet recruiting
  • Irmandade da Santa Casa de Misericórdia Hospital - Porto Alegre
    Porto Alegre, Rio Grande do Sul 90440-010, Brazil
    Not yet recruiting
  • Hospital Mãe de Deus - Centro Integrado de Oncologia
    Porto Alegre, Rio Grande do Sul 91210-250, Brazil
    Not yet recruiting
  • Grupo ELORA
    Florianópolis, Santa Catarina 88020-210, Brazil
    Not yet recruiting
  • CHO Centro - Centro de Hematologia e Oncologia de Joinville
    Joinville, Santa Catarina 89201-260, Brazil
    Not yet recruiting
  • Fundação Pio XII - Hospital de Câncer de Barretos - Hospital de Amor
    Barretos, São Paulo 14784-400, Brazil
    Not yet recruiting
  • Hospital Amaral Carvalho
    Jaú, São Paulo 17210-180, Brazil
    Not yet recruiting
  • A Beneficência Portuguesa de São Paulo
    São Paulo, São Paulo 01323-001, Brazil
    Not yet recruiting
  • Instituto de Assistência Médica ao Servidor Público Estadual
    São Paulo, São Paulo 04039-004, Brazil
    Not yet recruiting
  • Instituto de Oncologia de Sorocaba
    Sorocaba, São Paulo 18030-005, Brazil
    Not yet recruiting
  • Cross Cancer Institute
    Edmonton, Alberta T6G1Z2, Canada
    Not yet recruiting
  • William Osler Health System - Brampton Civic Hospital
    Brampton, Ontario L6R317, Canada
    Not yet recruiting
  • London Health Sciences Centre
    London, Ontario N6A 4G5, Canada
    Not yet recruiting
  • Sunnybrook Health Sciences Centre - Bayview Campus
    Toronto, Ontario M4N3M5, Canada
    Not yet recruiting
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G2M9, Canada
    Recruiting
  • Hôpital Saint-André
    Bordeaux, Aquitane 33000, France
    Recruiting
  • Hôpital Louis Pradel
    Bron, Auvergne-Rhône-Alpes 69500, France
    Recruiting
  • Hôpital de la Croix Rousse
    Lyon, Auvergne-Rhône-Alpes 69004, France
    Recruiting
  • Centre Léon Bérard
    Lyon, Auvergne-Rhône-Alpes 69008, France
    Recruiting
  • Centre Hospitalier Lyon-Sud
    Pierre-Bénite, Auvergne-Rhône-Alpes 69495, France
    Recruiting
  • L'Hôpital Nord-Ouest (HNO) - Villefranche-sur-Saône
    Villefranche-de-Rouergue, Aveyron 12200, France
    Not yet recruiting
  • Hôpital Côte De Nacre
    Caen, Basse-Normandie 14033, France
    Recruiting
  • Centre Hospitalier Universitaire de Nîmes
    Nîmes, Gard 30029, France
    Not yet recruiting
  • Hôpital Emile Muller
    Mulhouse, Grand Est 8051, France
    Recruiting
  • Hôpital Pontchaillou
    Rennes, Ille-et-Vilaine 35033, France
    Recruiting
  • Centre Hospitalier Universitaire De Nantes - Hôpital Nord Laennec
    Saint-Herblain, Loire-Atlantique 44800, France
    Recruiting
  • Centre Hospitalier Universitaire d'Angers
    Angers, Maine-et-Loire 49 933, France
    Not yet recruiting
  • CHU d Angers
    Angers, Maine-et-Loire 49 933, France
    Recruiting
  • Institut de Cancérologie de l'Ouest - Angers
    Angers, Maine-et-Loire 49055, France
    Recruiting
  • CHU de Nimes - Caremeau Nord
    Nîmes, Occitanie 30029, France
    Recruiting
  • Hôpital Universitaire Pitié Salpêtrière
    Paris, Paris 75013, France
    Recruiting
  • Centre Hospitalier Le Mans
    Le Mans, Pays de la Loire Region 72037, France
    Recruiting
  • Hopital Prive du Confluet
    Nantes, Pays de la Loire Region 44277, France
    Recruiting
  • Hôpital Privé du Confluent
    Nantes, Pays de la Loire Region 44277, France
    Not yet recruiting
  • Hopital Nord Ouest
    Gleizé, Rhône 69 655, France
    Recruiting
  • Gustave Roussy
    Villejuif, Val-De-Marne 94800, France
    Not yet recruiting
  • Hôpital Ambroise-Paré
    Boulogne-Billancourt, Île-de-France Region 92100, France
    Recruiting
  • Centre Hospitalier Intercommunal de Créteil
    Créteil, Île-de-France Region 94000, France
    Recruiting
  • Groupe Hospitalier Paris Saint-Joseph
    Paris, Île-de-France Region 75014, France
    Recruiting
  • Hôpital Bichat - Claude-Bernard
    Paris, Île-de-France Region 75018, France
    Recruiting
  • SLK-Kliniken - Fachklinik Löwenstein
    Löwenstein, Baden-Wurttemberg 74245, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Krankenhaus Nordwest
    Frankfurt am Main, Hesse 60488, Germany
    Not yet recruiting
  • Universitätsklinikum Gießen und Marburg - Gießen
    Giessen, Hesse 35392, Germany
    Not yet recruiting
  • Kliniken der Stadt Köln
    Cologne, North Rhine-Westphalia 51067, Germany
    Recruiting

Showing the first 100 of 253 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2029, 45 months after the start.

Of 62 industry-sponsored phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's planned 45 months is above that.

Counting every sponsor, half of 128 studies reached it within 44 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Aug 17, 2025
StartActual
Dec 22, 2025
Primary completionEst.
Oct 1, 2029
CompletionEst.
Oct 1, 2032
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 13, 2026
Sites
1 site added. 250 sites changed recruiting status (142 now not yet recruiting, 107 now recruiting, …)
Show 250 sites
  • Alaska Oncology and Hematology · Anchorage, United Statesno status→Recruiting
  • City of Hope Comprehensive Cancer Center - Duarte · Duarte, United Statesno status→Not yet recruiting
  • City of Hope Comprehensive Cancer Center Orange County Lennar Foundation Cancer Center · Irvine, United Statesno status→Not yet recruiting
  • Scripps Clinic Torrey Pines · La Jolla, United Statesno status→Not yet recruiting
  • Kaiser Permanente - Vallejo Medical Center · Vallejo, United Statesno status→Not yet recruiting
  • Georgetown University School of Medicine · Washington D.C., United Statesno status→Recruiting
  • D&H Cancer Research Center - Margate · Margate, United Statesno status→Recruiting
  • Alpha Oncology Research · Orange City, United Statesno status→Recruiting
  • City of Hope - Atlanta · Newnan, United Statesno status→Not yet recruiting
  • University of Illinois Medical Center · Chicago, United Statesno status→Recruiting
  • Profound Research LLC at Michigan Hematology and Oncology Consultants · Dearborn, United Statesno status→Recruiting
  • Henry Ford Health System · Detroit, United Statesno status→Not yet recruiting
  • Memorial Sloan Kettering Cancer Center - Basking Ridge · Basking Ridge, United Statesno status→Not yet recruiting
  • Memorial Sloan Kettering Cancer Center - Monmouth · Middletown, United Statesno status→Not yet recruiting
  • Memorial Sloan Kettering Cancer Center - Bergen · Montvale, United Statesno status→Not yet recruiting
  • Memorial Sloan Kettering Cancer Center - Commack · Commack, United Statesno status→Not yet recruiting
  • Memorial Sloan Kettering Cancer Center - Westchester · East White Plains, United Statesno status→Not yet recruiting
  • Long Island Jewish Medical Center · Lake Success, United Statesno status→Not yet recruiting
  • Perlmutter Cancer Center - 34th Street · New York, United Statesno status→Not yet recruiting
  • Memorial Sloan Kettering Cancer Center - New York · New York, United Statesno status→Recruiting
  • Memorial Sloan Kettering Cancer Center - Nassau · Uniondale, United Statesno status→Not yet recruiting
  • Atrium Health Wake Forest Baptist - Comprehensive Cancer Center · Charlotte, United Statesno status→Not yet recruiting
  • Durham Veterans Affairs Health Care System · Durham, United Statesno status→Not yet recruiting
  • Gabrail Cancer and Research Center · Canton, United Statesno status→Recruiting
  • Gibbs Cancer Center and Research Institute Spartanburg · Spartanburg, United Statesno status→Not yet recruiting
  • Virginia Cancer Specialists - Arlington Office · Arlington, United Statesno status→Not yet recruiting
  • Virginia Cancer Specialists - Fairfax Office · Fairfax, United Statesno status→Recruiting
  • Virginia Cancer Specialists - Bristow Office · Manassas, United Statesno status→Not yet recruiting
  • Virginia Cancer Specialists - Reston · Reston, United Statesno status→Not yet recruiting
  • Virginia Cancer Specialists - Woodbridge Office · Woodbridge, United Statesno status→Not yet recruiting
  • …and 220 more on the registry record
Show site
  • 4 Wojskowy Szpital Kliniczny z Polikliniką SP ZOZ · Wroclaw, Poland
Oct 13, 2026
Contact
Study contact now listed: added m•••@taihooncology.com · •••2446. See the current contact
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Active, not recruiting→Recruiting
    1 site added. 252 sites changed recruiting status (143 now not yet recruiting, 108 now recruiting, …)
    Show 252 sites
    • Alaska Oncology and Hematology · Anchorage, United Statesno status→Recruiting
    • City of Hope Comprehensive Cancer Center - Duarte · Duarte, United Statesno status→Not yet recruiting
    • City of Hope Comprehensive Cancer Center Orange County Lennar Foundation Cancer Center · Irvine, United Statesno status→Not yet recruiting
    • Scripps Clinic Torrey Pines · La Jolla, United Statesno status→Not yet recruiting
    • Kaiser Permanente - Vallejo Medical Center · Vallejo, United Statesno status→Not yet recruiting
    • Georgetown University School of Medicine · Washington D.C., United Statesno status→Recruiting
    • D&H Cancer Research Center - Margate · Margate, United Statesno status→Recruiting
    • Alpha Oncology Research · Orange City, United Statesno status→Recruiting
    • City of Hope - Atlanta · Newnan, United Statesno status→Not yet recruiting
    • University of Illinois Medical Center · Chicago, United Statesno status→Recruiting
    • Profound Research LLC at Michigan Hematology and Oncology Consultants · Dearborn, United Statesno status→Recruiting
    • Henry Ford Health System · Detroit, United Statesno status→Not yet recruiting
    • Memorial Sloan Kettering Cancer Center - Basking Ridge · Basking Ridge, United Statesno status→Not yet recruiting
    • Memorial Sloan Kettering Cancer Center - Monmouth · Middletown, United Statesno status→Not yet recruiting
    • Memorial Sloan Kettering Cancer Center - Bergen · Montvale, United Statesno status→Not yet recruiting
    • Memorial Sloan Kettering Cancer Center - Commack · Commack, United Statesno status→Not yet recruiting
    • Memorial Sloan Kettering Cancer Center - Westchester · East White Plains, United Statesno status→Not yet recruiting
    • Long Island Jewish Medical Center · Lake Success, United Statesno status→Not yet recruiting
    • Perlmutter Cancer Center - 34th Street · New York, United Statesno status→Not yet recruiting
    • Memorial Sloan Kettering Cancer Center - New York · New York, United Statesno status→Recruiting
    • Memorial Sloan Kettering Cancer Center - Nassau · Uniondale, United Statesno status→Not yet recruiting
    • Atrium Health Wake Forest Baptist - Comprehensive Cancer Center · Charlotte, United Statesno status→Not yet recruiting
    • Durham Veterans Affairs Health Care System · Durham, United Statesno status→Not yet recruiting
    • Gabrail Cancer and Research Center · Canton, United Statesno status→Recruiting
    • Gibbs Cancer Center and Research Institute Spartanburg · Spartanburg, United Statesno status→Not yet recruiting
    • Virginia Cancer Specialists - Arlington Office · Arlington, United Statesno status→Not yet recruiting
    • Virginia Cancer Specialists - Fairfax Office · Fairfax, United Statesno status→Recruiting
    • Virginia Cancer Specialists - Bristow Office · Manassas, United Statesno status→Not yet recruiting
    • Virginia Cancer Specialists - Reston · Reston, United Statesno status→Not yet recruiting
    • Virginia Cancer Specialists - Woodbridge Office · Woodbridge, United Statesno status→Not yet recruiting
    • …and 222 more on the registry record
    Show site
    • 4 Wojskowy Szpital Kliniczny z Polikliniką SP ZOZ · Wroclaw, Poland
    Contact Study contact now listed: added m•••@taihooncology.com · •••2446. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07128199
Responsible party
Sponsor
First posted
Aug 17, 2025
Start date
Dec 22, 2025
Primary completion
Oct 1, 2029 (estimated)
Completion
Oct 1, 2032 (estimated)
Last update
Oct 13, 2026

Study contacts

Taiho Oncology, Inc.
Contact
medicalinformation@taihooncology.com
+1 844-878-2446

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zipalertinib

Start the discussion